TRILYTE- polyethylene glyocol 3350, sodium chloride, sodium bicarbonate and potassium chloride powder, for solution

Drug Labeling and Warnings

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    TRILYTE is indicated for bowel cleansing prior to colonoscopy in adults and pediatric patients aged 6 months or greater.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Dosage Overview

    • TRILYTE, supplied as a powder, must be reconstituted with water before its use; it is not for direct ingestion [see Dosage and Administration (2.2), Warnings and Precautions (5.8)].

    • Do not reconstitute with other liquids and/or add starch-based thickeners to the mixing container [see Warnings and Precautions (5.7)].

    • The 4-liter reconstituted TRILYTE solution contains: 420 grams of polyethylene glycol (PEG) 3350, 5.72 grams of sodium bicarbonate, 11.2 grams of sodium chloride, 1.48 grams of potassium chloride, lemon flavor (contains dl-alpha-tocopherol and maltodextrin) 1.597 g and saccharin sodium 0.199 g.


    2.2 Administration Instructions Prior to Dosage

    On the day prior to the colonoscopy, instruct patients to:


    a)       Take only clear liquids, but avoid red and purple liquids. Patients may consume a light breakfast.

    b)    Early in the evening prior to colonoscopy, fill the supplied container containing the TRILYTE powder with lukewarm water (to facilitate dissolution) to the 4 liter fill line. The solution is clear and colorless when reconstituted to a final volume of 4 liters.

    c)     After capping the container, shake vigorously several times to ensure that the ingredients are dissolved. When reconstituted use within 48 hours.

    2.3 Dosage

    The following is the recommended dose of reconstituted TRILYTE solution for adults and pediatric patients ≥ 6 months. Instruct patients they may consume water or clear liquids during the bowel preparation and after completion of the bowel preparation up until 2 hours before the time of the colonoscopy. The solution is more palatable if chilled prior to administration.


    • Adults: Instruct patients to drink a total of up to 4 liters at a rate of 240 mL (8 oz.) every 10 minutes, until 4 liters are consumed or the rectal effluent is clear. Rapid drinking of each portion is preferred to drinking small amounts continuously. For NGT, rate is 20 to 30 mL per minute (1.2 to 1.8 liters per hour).
    • Pediatric Patients ≥ 6 Months: Pediatric patients should drink 25 mL/kg/hour until the stool is watery, clear, and free of solid matter. If pediatric patients are unable to drink the reconstituted TRILYTE solution, the solution may be given by nasogastric (NGT). NGT administration is at the rate of 25 mL/kg/hour.

    The first bowel movements should occur approximately one hour after the start of TRILYTE administration. Continue drinking until the watery stool is clear and free of solid matter.

  • 3 DOSAGE FORMS AND STRENGTHS

    For oral solution: One 4 liter jug with powder for reconstitution with water.


    Each 4 liter jug contains: polyethylene glycol 3350 USP 420 g, sodium bicarbonate USP 5.72 g, sodium chloride USP 11.2 g, potassium chloride USP 1.48 g, lemon flavor (contains dl-alpha-tocopherol and maltodextrin) 1.597 g and saccharin sodium 0.199 g.  When made up to 4 liters volume with water, the solution contains PEG 3350 31.3 mmol/L, sodium 65 mmol/L, chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.

  • 4 CONTRAINDICATIONS

    TRILYTE is contraindicated in the following conditions:


    • Gastrointestinal (GI) obstruction, ileus, or gastric retention
    • Bowel perforation
    • Toxic colitis or toxic megacolon
    • Known allergy or hypersensitivity to any component of TRILYTE [see How Supplied/Storage and Handling (16)]
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Serious Fluid and Serum Chemistry Abnormalities

    Advise patients to hydrate adequately before, during, and after the use of TRILYTE. Use caution in patients with congestive heart failure when replacing fluids. If a patient develops significant vomiting or signs of dehydration including signs of orthostatic hypotension after taking TRILYTE, consider performing post-colonoscopy lab tests (electrolytes, creatinine, and BUN) and treat accordingly. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures and renal impairment. Fluid and electrolyte abnormalities should be corrected before treatment with TRILYTE.


    In addition, use caution when prescribing TRILYTE for patients who have conditions, or who are using medications, that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and renal impairment [see Drug Interactions (7.1)].

    5.2 Cardiac Arrhythmias

    There have been rare reports of serious arrhythmias associated with the use of ionic osmotic laxative products for bowel preparation. Use caution when prescribing TRILYTE for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). Pre-dose and post-colonoscopy ECGs should be considered in patients at increased risk of serious cardiac arrhythmias.

    5.3 Seizures

    There have been reports of generalized tonic-clonic seizures and/or loss of consciousness associated with use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities.


    Use caution when prescribing TRILYTE for patients with a history of seizures and in patients at increased risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected hyponatremia.

    5.4 Renal Impairment

    Use caution when prescribing TRILYTE for patients with impaired renal function or patients taking concomitant medications that may affect renal function (such as diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or non-steroidal anti-inflammatory drugs). Advise these patients of the importance of adequate hydration, and consider performing baseline and post- colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients.

    5.5 Colonic Mucosal Ulcerations and Ischemic Colitis

    Administration of osmotic laxative products may produce colonic mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of stimulant laxatives and TRILYTE may increase this risk. The potential for mucosal ulcerations resulting from the bowel preparation should be considered when interpreting colonoscopy findings in patients with known or suspect inflammatory bowel disease (IBD).

    5.6 Use in Patients with Significant Gastrointestinal Disease

    If gastrointestinal obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administering TRILYTE. If a patient experiences severe bloating, distention or abdominal pain, administration should be slowed or temporarily discontinued until the symptoms abate. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed to rule out these conditions before administration of TRILYTE.


    Use with caution in patients with severe active ulcerative colitis.

    5.7 Aspiration

    Use with caution in patients with impaired gag reflex, unconscious, or semiconscious patients, and patients prone to regurgitation or aspiration. Such patients should be observed during administration of TRILYTE, especially if it is administered via nasogastric tube.


    Do not combine TRILYTE with starch-based thickeners [see Dosage and Administration (2.1)]. Polyethylene glycol (PEG), a component of TRILYTE, when mixed with starch-thickened liquids reduces the viscosity of the starch-thickened liquid. When a PEG-based product used for another indication was mixed in starch-based pre-thickened liquids used in patients with dysphagia, thinning of the liquid occurred and cases of choking and potential aspiration were reported.

    5.8 Not for Direct Ingestion

    The contents of each jug must be diluted with water to a final volume of 4 liters (4 L) and ingestion of additional water is important to patient tolerance. Direct ingestion of the undissolved powder may increase the risk of nausea, vomiting, dehydration, and electrolyte disturbances.

  • 6 ADVERSE REACTIONS

    The following serious or otherwise important adverse reactions are described elsewhere in the labeling:

    The following adverse reactions have been identified during post-approval use of TRILYTE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.


    Nausea, abdominal fullness and bloating are the most common adverse reactions (occurred in up to 50% of patients) to administration of TRILYTE. Abdominal cramps, vomiting and anal irritation occur less frequently. These adverse reactions are transient and usually subside rapidly. Isolated cases of urticaria, rhinorrhea, dermatitis and (rarely) anaphylactic reaction have been reported which may represent allergic reactions.


    Published literature contains isolated reports of serious adverse reactions following the administration of PEG-electrolyte solution products in patients over 60 years of age. These adverse events include upper GI bleeding from Mallory-Weiss Tear, esophageal perforation, asystole, sudden dyspnea with pulmonary edema, and “butterfly-like” infiltrates on chest X-ray after vomiting and aspirating PEG.

  • 7 DRUG INTERACTIONS

    7.1 Drugs that May Lead to Fluid and Electrolyte Abnormalities

    Use caution when prescribing TRILYTE for patients who are using medications that increase the risk for fluid and electrolyte disturbances or may increase the risk of adverse events of seizure, arrhythmias, and prolonged QT in the setting of fluid and electrolyte abnormalities. Consider additional patient evaluations as appropriate [see Warnings and Precautions (5.1, 5.2, 5.3, and 5.4)] in patients taking these concomitant medications.

    7.2 Potential for Altered Drug Absorption

    Oral medication administered within one hour of the start of administration of TRILYTE may be flushed from the gastrointestinal tract and the medication may not be absorbed properly.

    7.3 Stimulant Laxatives

    Concurrent use of stimulant laxatives and TRILYTE may increase the risk of mucosal ulceration or ischemic colitis. Avoid use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) while taking TRILYTE.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Animal reproduction studies have not been conducted with TRILYTE. It is also not known whether TRILYTE can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. TRILYTE should be given to a pregnant woman only if clearly needed.

    8.3 Nursing Mothers

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TRILYTE is administered to a nursing woman.

    8.4 Pediatric Use

    Safety and effectiveness of TRILYTE in pediatric patients aged 6 months and older is supported by evidence from adequate and well-controlled clinical trials of TRILYTE in adults with additional safety and efficacy data from published studies of similar formulations. Use of TRILYTE in children younger than 2 years of age should be carefully monitored for occurrence of possible hypoglycemia, as this solution has no caloric substrate. Dehydration has been reported in one child and hypokalemia has been reported in 3 children.

    8.5 Geriatric Use

    Clinical studies of TRILYTE did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

  • 11 DESCRIPTION

    For oral solution: Each 4 liter (4 L) TRILYTE jug contains a white to off white powder for reconstitution. TRILYTE is a combination of polyethylene glycol 3350, an osmotic laxative, and electrolytes (sodium chloride, sodium bicarbonate and potassium chloride) for oral solution.


    Each 4 liter jug contains: polyethylene glycol 3350 USP 420 g, sodium bicarbonate USP 5.72 g, sodium chloride USP 11.2 g, potassium chloride USP 1.48 g, lemon flavor (contains dl-alpha-tocopherol and maltodextrin) 1.597 g and saccharin sodium 0.199 g. The solution is clear and colorless when reconstituted to a final volume of 4 liters with water.

               

    Polyethylene Glycol 3350, USP


    Chemical Structure 1


    Sodium Bicarbonate, USP

    The chemical name is NaHCO3. The average Molecular Weight is 84.01. The structural formula is:


    Chemical Structure 2


    Sodium Chloride, USP

    The chemical name is NaCl. The average Molecular Weight: 58.44. The structural formula is:

    Na+ Cl-


    Potassium Chloride, USP

    The chemical name is KCl. The average Molecular Weight: 74.55. The structural formula is:

    K-Cl

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The primary mode of action is thought to be through the osmotic effect of polyethylene glycol 3350 which causes water to be retained in the colon and produces a watery stool.

    12.2 Pharmacodynamics

    TRILYTE induces as diarrhea which rapidly cleanses the bowel, usually within four hours.

    12.3 Pharmacokinetics

    The pharmacokinetics of PEG 3350 following administration of TRILYTE were not assessed. Available pharmacokinetic information for oral PEG 3350 suggests that it is poorly absorbed.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Long term studies in animals have not been performed to evaluate carcinogenic potential of TRILYTE. Studies to evaluate the possible impairment of fertility or mutagenic potential of TRILYTE have not been performed.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    In powdered form, for oral administration as a solution following reconstitution. TRILYTE is available in a disposable jug in powdered form containing:


    TRILYTE: polyethylene glycol 3350 USP 420 g, sodium bicarbonate USP 5.72 g, sodium chloride USP 11.2 g, potassium chloride USP 1.48 g, lemon flavor (contains dl-alpha-tocopherol and maltodextrin) 1.597 g and saccharin sodium 0.199 g. When made up to 4 liters volume with water, the solution contains PEG 3350 31.3 mmol/L, sodium 65 mmol/L, chloride 53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.


    5 Liter disposable jug with a 4 Liter fill line  NDC: 84386-013-04

    Storage: Store in sealed container at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF). [See USP Controlled Room Temperature.] When reconstituted, keep solution refrigerated. Use within 48 hours. Discard unused portion.


    Keep out of reach of children.

  • 17 PATIENT COUNSELING INFORMATION

    See FDA-Approved Patient Labeling (Medication Guide). Instruct patients:


    • To let you know if they have trouble swallowing or are prone to regurgitation or aspiration.
    • Not to take other laxatives while they are taking TRILYTE.
    • To consume water or clear liquids during the bowel preparation and after completion of the bowel preparation up until 2 hours before the time of the colonoscopy.
    • That if they experience severe bloating, distention or abdominal pain, the administration of the solution should be slowed or temporarily discontinued until the symptoms abate. Advise patients to report these events to their health care provider.
    • That if they have hives, rashes, or any allergic reaction, they should discontinue the medication and contact their health care provider. Medication should be discontinued until they speak to their physician.
    • To contact their healthcare provider if they develop signs and symptoms of dehydration [see Warnings and Precautions (5.1)].
    • That oral medication administered within one hour of the start of administration of TRILYTE solution may be flushed from the GI tract and the medication may not be absorbed completely.

    Distributed by:
    Aurobindo Pharma USA, Inc.
    279 Princeton-Hightstown Road
    East Windsor, NJ 08520

    Manufactured by:
    Aurobindo Pharma Limited
    Hyderabad-500 032, India

    Revised: 12/2025 

  • Medication Guide

    TRILYTE

    (traI-laIt)

    (PEG 3350, sodium chloride, sodium bicarbonate and potassium chloride oral solution)


    Read this Medication Guide before you start taking TRILYTE. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.


    What is the most important information I should know about TRILYTE?


    TRILYTE and other osmotic bowel preparations can cause serious side effects, including:


    Serious loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood.


    These changes can cause:

    • abnormal heartbeats that can cause death
    • seizures. This can happen even if you have never had a seizure.
    • kidney problems

    Your chance of having fluid loss and changes in body salts with TRILYTE is higher if you:

    • have heart problems
    • have kidney problems
    • take water pills or non-steroidal anti-inflammatory drugs (NSAIDS)

    Tell your healthcare provider right away if you have any of these symptoms of a loss of too much body fluid (dehydration) while taking TRILYTE:


    • vomiting that prevents you from keeping down the solution
    • dizziness
    • urinating less often than normal
    • headache

    See Section “What are the possible side effects of TRILYTE” for more information about side effects.

    What is TRILYTE?


    TRILYTE is a prescription medicine used by adults to clean the colon before a colonoscopy. TRILYTE cleans your colon by causing you to have diarrhea. Cleaning your colon helps your healthcare provider see the inside of your colon more clearly during your colonoscopy.


    TRILYTE is safe and effective for use in pediatric patients aged 6 months and older.

    Who should not take TRILYTE?


    Do not take TRILYTE if your healthcare provider has told you that you have:

    • a blockage in your bowel (obstruction)
    • an opening in the wall of your stomach or intestine (bowel perforation)
    • problems with food and fluid emptying from your stomach (gastric retention)
    • a very dilated intestine (bowel)
    • an allergy to any of the ingredients in TRILYTE. See the end of this leaflet for a complete list of ingredients in TRILYTE.

    What should I tell my healthcare provider before taking TRILYTE? Before you take TRILYTE, tell your healthcare provider if you:


    • have heart problems
    • have stomach or bowel problems
    • have ulcerative colitis
    • have problems with swallowing or gastric reflux
    • have a history of seizures
    • are withdrawing from drinking alcohol
    • have a low blood salt (sodium) level
    • have kidney problems
    • any other medical conditions
    • are pregnant. It is not known if TRILYTE will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.
    • are breastfeeding or plan to breastfeed. It is not known if TRILYTE passes into your breast milk. You and your healthcare provider should decide if you will take TRILYTE while breastfeeding.

    Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.


    TRILYTE may affect how other medicines work. Medicines taken by mouth may not be absorbed properly when taken within 1 hour before the start of TRILYTE.

    Especially tell your healthcare provider if you take:

    • medicines for blood pressure or heart problems
    • medicines for kidney problems
    • medicines for seizures
    • water pills (diuretics)
    • non-steroidal anti-inflammatory medicines (NSAID) pain medicines
    • laxatives
    • starch-based thickeners. For patients who have trouble swallowing, do not mix TRILYTE with starch-based thickeners.

    Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure if you are taking any of the medicines listed above.


    Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

    How should I take TRILYTE?


    You must read, understand, and follow these instructions to take TRILYTE the right way.

    • Take TRILYTE exactly as your healthcare provider tells you to take it.
    • Drink 240 mL (8 oz.) every 10 minutes. Rapid drinking of each portion is better than drinking small amounts.
    • The first bowel movement should occur approximately one hour after you start drinking the solution.
    • You may experience some abdominal bloating and distention before the bowels start to move. If severe discomfort or distention occur, stop drinking temporarily or drink each portion at longer intervals until the discomfort goes away.
    • Continue drinking until the watery stool is clear and free of solid matter. This usually requires 3 liters and it is best to drink all of the solution.
    • Do not take undissolved TRILYTE powder that has not been mixed with water (diluted), it may increase your risk of nausea, vomiting and fluid loss (dehydration).
    • Each jug of TRILYTE must be reconstituted with water (diluted) to 4 liters total volume before drinking.
    • Do not take other laxatives while taking TRILYTE.
    • Do not eat solid foods on the day before your colonoscopy and until after your colonoscopy. Drink only clear liquids:
      • the day before your colonoscopy
      • while taking TRILYTE
      • after taking TRILYTE until 2 hours before your colonoscopy

    What are the possible side effects of TRILYTE?


    TRILYTE can cause serious side effects, including:


    • See Section “What is the most important information I should know about TRILYTE?”
    • changes in certain blood tests. Your healthcare provider may do blood tests after you take TRILYTE to check your blood for changes. Tell your healthcare provider if you have any symptoms of too much fluid loss, including:  
      • vomiting
      • nausea
      • bloating
      • dizziness
      • stomach (abdominal) cramping
      • headache
      • urinate less than usual
      • trouble drinking clear liquid
    • heart problems. TRILYTE may cause irregular heartbeats.
    • seizures
    • ulcers of the bowel or bowel problems (ischemic colitis). Tell your healthcare provider right away if you have severe stomach-area (abdomen) pain or rectal bleeding.

    The most common side effects of TRILYTE include:

    • nausea
    • stomach (abdominal) fullness
    • bloating
    • stomach (abdominal) cramps
    • vomiting
    • anal irritation

    Tell your healthcare provider if you have any side effect that bothers you or that does not go away.


    These are not all the possible side effects of TRILYTE. For more information, ask your healthcare provider or pharmacist.


    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


    How should I store TRILYTE?


    • Store TRILYTE at room temperature, between 15º to 30°C (59º to 86°F).

    Keep TRILYTE and all medicines out of the reach of children.

    General information about the safe and effective use of TRILYTE.


    Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TRILYTE for a condition for which it was not prescribed. Do not give TRILYTE to other people, even if they are going to have the same procedure you are. It may harm them.


    This Medication Guide summarizes important information about TRILYTE. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information that is written for healthcare professionals.


    For more information, call Aurobindo Pharma USA, Inc. at 1-866-850-2876.


    What are the ingredients in TRILYTE?


    Active ingredients: polyethylene glycol 3350, sodium bicarbonate, sodium chloride, and potassium chloride.  


    Inactive ingredients: lemon flavor (contains dl-alpha-tocopherol and maltodextrin) and saccharin sodium.


    This Medication Guide has been approved by the U.S. Food and Drug Administration.


    Distributed by:
    Aurobindo Pharma USA, Inc.
    279 Princeton-Hightstown Road
    East Windsor, NJ 08520

    Manufactured by:
    Aurobindo Pharma Limited
    Hyderabad-500 032, India

    Revised: 12/2025

  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 4 liters Bottle Label

    NDC: 84386-013-04
    FILL TO THE TOP OF THE LINE ON BOTTLE

    Rx only
    Trilyte® (PEG 3350, sodium chloride,
    sodium bicarbonate, and potassium
    chloride for oral solution)

    To Pharmacist and Patient: Mixing information is on base label.
    Package insert may be removed before dispensing.

    Dispense the Medication Guide provided separately to each patient.


    WITH LEMON FLAVOR

    When reconstituted with water to a volume for 4 liters, this solution
    contains PEG 3350 31.3 mmol/L, sodium 65 mmol/L, chloride
    53 mmol/L, bicarbonate 17 mmol/L and potassium 5 mmol/L.


    Each disposable jug contains, in powdered form:

    Polyethylene Glycol 3350 USP                                                         420 g
    Sodium Bicarbonate USP                                                                 5.72 g
    Sodium Chloride USP                                                                      11.2 g
    Potassium Chloride USP                                                                  1.48 g
    Lemon Flavor (contains dl-alpha-tocopherol and maltodextrin)     1.597 g
    Saccharin Sodium                                                                             0.199 g

    Store in sealed container at 25ºC (77ºF); excursions permitted between 15º to 30ºC
    (59º to 86ºF). [See USP Controlled Room Temperature.]

       

    PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 4 liters Bottle Label

  • INGREDIENTS AND APPEARANCE
    TRILYTE 
    polyethylene glyocol 3350, sodium chloride, sodium bicarbonate and potassium chloride powder, for solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 84386-013
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    POLYETHYLENE GLYCOL 3350 (UNII: G2M7P15E5P) (POLYETHYLENE GLYCOL 3350 - UNII:G2M7P15E5P) POLYETHYLENE GLYCOL 3350420 g  in 4 L
    SODIUM BICARBONATE (UNII: 8MDF5V39QO) (SODIUM CATION - UNII:LYR4M0NH37, BICARBONATE ION - UNII:HN1ZRA3Q20) SODIUM BICARBONATE5.72 g  in 4 L
    SODIUM CHLORIDE (UNII: 451W47IQ8X) (SODIUM CATION - UNII:LYR4M0NH37, CHLORIDE ION - UNII:Q32ZN48698) SODIUM CHLORIDE11.2 g  in 4 L
    POTASSIUM CHLORIDE (UNII: 660YQ98I10) (POTASSIUM CATION - UNII:295O53K152, CHLORIDE ION - UNII:Q32ZN48698) POTASSIUM CHLORIDE1.48 g  in 4 L
    Inactive Ingredients
    Ingredient NameStrength
    .ALPHA.-TOCOPHEROL, DL- (UNII: 7QWA1RIO01)  
    MALTODEXTRIN (UNII: 7CVR7L4A2D)  
    SACCHARIN SODIUM (UNII: SB8ZUX40TY)  
    Product Characteristics
    ColorWHITE (white to off white) Score    
    ShapeSize
    FlavorLEMONImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 84386-013-044 L in 1 BOTTLE; Type 0: Not a Combination Product04/14/2026
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07649104/14/2026
    Labeler - Aurobindo Pharma Limited (650082092)
    Establishment
    NameAddressID/FEIBusiness Operations
    APL HEALTHCARE LIMITED650844777ANALYSIS(84386-013) , MANUFACTURE(84386-013)
    • © 2026 FDA.report
    This site is not affiliated with or endorsed by the FDA.